Related Experiment Videos
Somatostatin attenuates ischemic intestinal injury
J B Morris1, N H Guerrero, E E Furth
1Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia 19104-4283.
American Journal of Surgery
|June 1, 1993
Summary
Octreotide acetate, a somatostatin analogue, reduced pancreatic proteases in rats, significantly lessening intestinal injury from ischemia. This suggests somatostatin may aid in preventing or managing ischemic intestinal damage.
Area of Science:
- Gastroenterology
- Surgical Research
- Pathophysiology
Background:
- Pancreatic proteases contribute significantly to ischemic intestinal injury.
- Targeting exocrine function may offer a therapeutic strategy for this condition.
Purpose of the Study:
- To investigate the efficacy of octreotide acetate, a somatostatin analogue, in attenuating ischemic intestinal injury.
- To determine if blocking pancreatic exocrine function reduces mucosal damage.
Main Methods:
- Sprague-Dawley rats were pretreated with octreotide acetate for 6 days.
- Splanchnic blood flow and duodenal trypsin activity were measured.
- Animals underwent superior mesenteric artery ischemia and reperfusion, with injury assessed by a blinded observer.
Main Results:
- Octreotide acetate reduced intraluminal duodenal trypsin activity by 46% without altering portal blood flow.
- Pretreatment significantly attenuated microscopic injury depth during ischemia.
- Octreotide acetate lessened the extent of gross injury following reperfusion.
Conclusions:
- Octreotide acetate effectively reduces pancreatic protease activity in the intestine.
- Somatostatin analogues may play an adjuvant role in preventing or mitigating intestinal ischemic injury.